XINXF yields 1.51% · JNJ yields 2.13%● Live data
📍 XINXF pulled ahead of the other in Year 1
Combined, XINXF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of XINXF + JNJ for your $10,000?
New Work SE operates professional networking platforms in Germany and internationally. It operates through B2C, B2B E-Recruiting, and B2B Marketing Solutions & Events segments. The B2C segment serves XING members who use xing.com, XING Jobs, and kununu.com or internations.org to network with other professionals for finding a suitable job, obtaining information about employers, or reading about career-related topics. The B2B E-Recruiting segment products portfolio includes Job ads (XJM), XING TalentManager (XTM), XING TalentPoolManager (XTP), XING Talent Referral Manager (XRM), Employee branding profile, Prescreen Applicant Tracking System, XING TalentService (XTS), XING 360 package, and Honeypot. This segment serves customers who seek access to employees and talent. The B2B Marketing Solutions & Events segment offers native, video, and content advertising formats, sponsored mailings, audience network, and event subsegment, as well as ticketing solutions. This segment serves advertising and events clients. The company was formerly known as Xing SE and changed its name to New Work SE in August 2019. The company was founded in 2003 and is based in Hamburg, Germany. New Work SE is a subsidiary of Burda Digital SE.
Full XINXF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.